These results suggested that CAFs could promote angiogenesis via PGF-VEGFR1 in ICC following ICB therapy, supporting the rationale for targeting VEGF and CAFs in ICC management. The gene discussed is FLT1; the disease is intrahepatic cholangiocarcinoma.